Coronavirus Infection and Cholesterol Metabolism

Jun Dai1,2,3†, Huan Wang2†, Ying Liao2, Lei Tan2, Yingjie Sun2, Cuiping Song2, Weiwei Liu2, Xusheng Qiu2* and Chan Ding2,4*

1 College of Animal Science and Technology, Guangxi University, Nanning, China, 2 Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China, 3 Experimental Animal Center, Zunyi Medical University, Zunyi City, China, 4 Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China

Host cholesterol metabolism remodeling is significantly associated with the spread of human pathogenic coronaviruses, suggesting virus-host relationships could be affected by cholesterol-modifying drugs. Cholesterol has an important role in coronavirus entry, membrane fusion, and pathological syncytia formation, therefore cholesterol metabolic mechanisms may be promising drug targets for coronavirus infections. Moreover, cholesterol and its metabolizing enzymes or corresponding natural products exert antiviral effects which are closely associated with individual viral steps during coronavirus replication. Furthermore, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 infections are associated with clinically significant low cholesterol levels, suggesting cholesterol could function as a potential marker for monitoring viral infection status. Therefore, weaponizing cholesterol dysregulation against viral infection could be an effective antiviral strategy. In this review, we comprehensively review the literature to clarify how coronaviruses exploit host cholesterol metabolism to accommodate viral replication requirements and interfere with host immune responses. We also focus on targeting cholesterol homeostasis to interfere with critical steps during coronavirus infection.

Keywords: coronavirus, cholesterol, metabolism dysregulation, immune response, therapy

INTRODUCTION

Coronaviruses are enveloped viruses with non-segmented, single-stranded, positive sense RNA genomes (1). They belong to the Nidovirales order in the Coronaviridae, and are divided into four types: α, β, γ, and δ (1, 2). Coronavirus subfamily members are widespread in infected birds and mammals and some respiratory and intestinal diseases (3–5). Currently, at least seven coronaviruses are known to infect humans, including respiratory syndrome coronavirus 2, human coronavirus OC43, human coronavirus NL63, human coronavirus 229E, severe acute respiratory syndrome coronavirus, human coronavirus HKU1, and Middle East respiratory syndrome coronavirus (6). Coronavirus diversity is due to the low fidelity of RNA-dependent RNA polymerase during viral coding which produces approximately $10^{-3}$–$10^{-5}$ substitutions/site/year (7). Previous evidence indicated that coronaviruses undergo rapid recombination which creates new strains with altered virulence (8). Recent studies reported molecular and serological evidence of the active transmission...
of SARS-CoV-2-associated coronavirus (SC2R-CoV) in bats in Southeast Asia (9). Closely related coronaviruses are found in distantly related animals; the consequences of this species barrier jump may be devastating and lead to serious disease and death, e.g., SARS-CoV and MERS-CoV are zoonotic viruses that have crossed the species barrier via bats/palm civets and dromedary camels, respectively (10). Beta-coronavirus spill over from Hipposideridae to Rhinolophidae, and then from Rhinolophidae to civets and humans (11). Swine Acute Diarrhea Syndrome CoV is derived from the species Rhinolophus bat coronavirus HKU2 which potentially infects rodents (12, 13). Mechanistically, the species barrier jump is believed to be due to a failure in specific interactions between the viral spike protein receptor binding domain (RBD) and the host receptor, angiotensin converting enzyme 2 (ACE2) (14). This mechanism demonstrated a major tendency to jump from animals to humans.

The COVID-19 pandemic caused by SARS-CoV-2 is the latest example of a major threat to human health (15). This marks the third time a highly pathogenic coronavirus was transmitted to humans from animals (16, 17). SARS-CoV-2 is believed to have originated in bats, however the intermediate host species and the transmission mode remains unclear (18, 19). Studies confirmed that SARS-CoV-2 replicates more easily in ferrets and cats when compared with dogs, pigs, chickens, and ducks (20). The main pathophysiological feature of SARS-CoV-2 is the excessive production of inflammatory factors, leading to systemic inflammation and multiple organ dysfunction syndrome, with an acute impact on the cardiovascular system and lung fibrosis (21–24). Since SARS-CoV-2 belongs to β-coronavirus family and is not a common human pathogen, humans lack a natural immunity to SARS-CoV-2 (25). Unfortunately, the development of novel coronavirus vaccines commenced too late to effectively control the first infection wave (26). Thus far, no specific, highly effective antiviral therapies are available. The disease has rapidly spread to more than 200 countries and territories (27–30). According to World Health Organization statistics, as of February 11th 2022, the total number of COVID-19 cases worldwide had reached 402,044,502, of which 5,770,023 had died (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). SARS-CoV-2 is estimated to have 2–4 times more affinity for ACE2 than the SARS virus (31). Multiple mutations have been identified in the viral S1 subunit, of which three are in the RBD. This not only increases RBD affinity for ACE2 but improves viral escape from the immune system (32). Currently (September 2021), several SARS-CoV-2 delta variants have become more infectious due to mutations in the S protein RBD, and they are also ORF8-deficient. These variants have rapidly spread globally, including outbreaks in the UK (33–36), Taiwan (37), Southeast Asia (38), Germany (39), France (40), USA (41), Poland (42), and Italy (43). Strikingly, ORF8-deficient variants had spread among domestic mink and pangolin in Denmark, and were detected in humans (44, 45). Thus, ORF8-deficient variants in unknown animal reservoirs pose great challenges to human public health and safety (46), thus monitoring such SARS-CoV-2 variants is critical for the prevention and control of the COVID-19 pandemic (36).

Previous studies reported that COVID-19 severity was related to several risk factors, for example, obesity, old age, and underlying disease (47–49). A recent study suggested that when compared to the normal population, cholesterol levels were significantly lower in COVID-19 patients (50). Furthermore, high-density lipoprotein cholesterol was lower in patients with severe and critical disease than in patients with moderate or mild disease, in a study on cholesterol metabolism in mild, moderate, severe, and critical COVID-19 patients (51). Age-specific COVID-19-associated death data from 45 countries showed that the infection fatality ratio was lowest among 5–9 year-old children, with a log-linear increase by age in individuals over 30 years old (52). In Spanish subjects over 75 years old, the lethality rate approached 36% in hospitalized patients, far higher than for younger groups under the same conditions in hospitals, despite having a similar course to younger individuals (53). In addition, Richter and Sohrabi studied obese factors in COVID-19 patients when compared with the normal population. In general, they observed that obese patients were twice as likely to develop COVID-19 as those with a normal weight range (34, 55). A study of clinical characteristics on 393 patients with COVID-19 in New York City, they found that respiratory failure, a severe clinical symptom of COVID-19, was more common among the obese patient subgroup, comprising 35.8% of the patients studied in New York. In addition, they also found that after advanced age, obesity was the most common risk factor leading to severe disease and death from COVID-19 (56). In addition to these factors, male sex, diabetes, smoking, hypertension, and cardiovascular disease also affect COVID-19 risk severity.

Importantly, transcriptomics data indicated that host cholesterol metabolism affects virus replication (57). Cholesterol content in the plasma membrane is extremely high and is important for biochemical and biophysical functions (58). As a unique feature of mammalian membranes, host cell cholesterol is targeted by pathogens (cytosolic bacteria and viruses) for entry and egress (59–63), however, a small number of coronavirus strains are distinct in terms of their dependence on cholesterol (64). Notwithstanding, a strong relationship between cholesterol and coronavirus replication is widely documented in the literature; in some instances, cholesterol is vital for coronavirus entry, membrane fusion, translation, pathological syncytia formation and vascular pathology (65–68) (Figure 1). Cholesterol metabolism may be hijacked by enveloped viruses to provide raw materials for virus particle replication, assembly, and maturation (69), e.g., Hepatitis C virus (HCV), human cytomegalovirus, and Epstein-Barr virus (70–72). For coronaviruses, cholesterol and other specific lipid requirements are required for viral replication scaffolds (73–75). Also, previous studies reported significant associations between cholesterol homeostasis and type I interferon (IFN) responses (76). Viral infections may induce host cells to alter the expression of cholesterol metabolizing enzymes and metabolites, and similarly, cholesterol metabolism can also regulate host antiviral responses (77, 78). Therefore, weaponizing host cholesterol metabolism dysregulation against coronavirus infectivity could be an effective antiviral strategy (79, 80).
Thus, cholesterol could be an important tool for the in-depth exploration of COVID-19 pathophysiology (81). The disruption of cholesterol homeostasis may interfere with critical steps of coronavirus infection, therefore understanding cholesterol functions during COVID-19 pathogenesis may generate improved prognostics and therapeutics (27). Recently, Daniloski et al. conducted a large-scale screen of > 20,000 drugs potentially used to treat COVID-19, and identified cholesterol biosynthesis pathway induction as a possible mechanism of viral inhibition (82, 83). The pharmacological inhibition of phosphatidylinositol kinases and cholesterol homeostasis reduced replication of all three coronaviruses. These findings provide important insights for an increased understanding of the coronavirus life cycle and the development of host-directed therapies (84). This review focuses on the latest scientific evidence and clarifies how coronaviruses manipulate host cholesterol metabolism to meet their own replication needs and impair host IFN responses. In addition, targeting and altering cholesterol levels in host cell membranes, and interfering with intracellular cholesterol metabolism pathways may be effective strategies in preventing early coronavirus cell entry and subsequent translation and replication. These approaches could provide foundations for the design of anti-coronavirus drug and treatment strategies (79, 85).

THE ROLE OF CHOLESTEROL METABOLISM DURING THE CORONAVIRUS LIFE CYCLE

Molecular Mechanisms of Coronavirus Entry

Coronavirus entry into host cells is key for virus replication cycles and evading host antiviral responses (86, 87). However, coronaviruses enter cells by two ways: 1) when sufficient proteases are present on plasma membranes, viruses exploit this by fusing with the cell through the “early pathway” via the plasma membrane, and 2) in the absence of extracellular proteases, endosomal proteases activate the viral S protein to
gain cell entry via the endosomal pathway (88) which is sensitive to the pH of endosome/lysosome pathways (89). Moreover, the infection efficiency of SARS-CoV in the cell in the "early pathway" is 100-1000 times higher than the endosomal pathway (90). Previous research reported that many coronaviruses, including infectious bronchitis virus (IBV), porcine hemagglutinating encephalomyelitis virus (PHEV), porcine epidemic diarrhea virus (PEDV), and feline coronavirus (FCoV) enter host cells via the endocytic pathway and then pass through endosomal compartments via multivesicular bodies (MVBs) to enter the cytoplasm (91–94). The coronavirus S protein plays a key role in early viral infection stages and is necessary for viral entry and chemotaxis in hosts (95). This protein is a type I homotrimeric transmembrane fusion glycoprotein, composed of S1 and S2 subunits with different functions. The RBD of the S1 subunit recognizes the cell receptor, ACE2, which determines cell homogeneity and pathogenicity of coronaviruses. The S2 subunit mediates virus and host cell membrane fusion via a wide range of conformational rearrangements (96–98). Moreover, the S1 subunit of SARS-2-S also binds to cholesterol and possibly high-density lipoprotein (HDL) components to enhance in vitro viral uptake; this mechanism is mediated by the HDL scavenger receptor B type 1 (99). In addition, the SARS-CoV-2 spike protein S1/S2 boundary sequence has key roles in regulating viral entry and spread within the cell (96). More importantly, S1/S2 border sequence deletion switches SARS-CoV-2 from the plasma membrane to the endosomal fusion pathway, significantly reducing viral transmission efficiency in hamsters (100). In particular, the S1/S2 boundary sequence contains a furin protease cleavage site which pre-activates the S protein for membrane fusion, reducing SARS-CoV-2 dependence on plasma membrane proteases (e.g., TMPRSS2), thereby efficiently improving cell entry (101). When compared with other coronaviruses, murine coronavirus (MHV) is unique; its receptor binding has dual roles when gaining cellular entry: the S protein N-terminal domain binds to the host receptor protein, CEACAM1a (102), then MHV uses a zinc metalloprotease for invasion and cell-cell fusion (103). This not only promotes MHV attachment to host cells, but also promotes MHV fusion with the host membrane (104). More specifically, the CEACAM1 receptor or a pH 8 induces conformational changes in the MHV S glycoprotein at 37°C. This conformational change is more conducive to triggering membrane fusion without the need to activate cleavage between S1 and S2 in advance (105).

Niemann-Pick disease type C (NPC) is a lysosomal storage disorder (106) caused by deficient lipid efflux from the late endosome/lysosome (LE/L) and induces intracellular cholesterol synthesis and transport disorders to impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms (79). By intervening in the NPC1 pathway, SARS-CoV-2 is blocked from entering the host cell from the plasma membrane or endosomes/lysosomes, thus viral infectivity is weakened (107). The Ebola virus requires a functional NPC1 protein to complete its replication cycle, however, it is unclear if this is true for coronaviruses (108). Studies reported that SARS-CoV particle transport through endosomes to NPC1 positive compartments of the lysosomal system was necessary for successful infection (109). Mingo et al. showed that Ebola virus reaching NPC1-positive LE/Ls was the rate-limiting step in determining viral infection (109). Furthermore, although SARS-CoV does not require NPC1 for entry, its entry into the cytoplasm begins after colocalization with NPC1 (109). Therefore, pharmacological interventions targeting lysosomal functions could induce transient NPC1-like cells and biochemical phenotypes, which could constitute a possible rationale for COVID-19 treatment (110). Drugs such as fluoxetine not only damage LE/L acidification but also accumulate cholesterol in these compartments (111).

**Host Cholesterol in Coronavirus Entry**

Coronavirus enters host cells mainly via plasma membrane fusion or endocytosis (112, 113). Lipid rafts participate in endocytosis-mediated processes, and function as platform and docking sites for coronavirus entry and genome release (114, 115). Cholesterol is an important component of lipid rafts; increased lipid raft formation is benefitted by increased cholesterol levels (116). Early coronavirus infection depends on lipid rafts (117) which may harbor ACE2 receptors for the SARS-CoV-2 S protein (118–121), permitting membrane rearrangements to facilitate transmissible gastroenteritis virus (TGEV) entry (122). In addition, lipid rafts act as attachment factors to promote IBV absorption before it enters the cell (119). MHV entry and membrane fusion also require lipid rafts (123). Membrane cholesterol consumption inhibits SARS-CoV-2 and other coronaviruses from fusing with cells, preventing viral entry (124, 125). By reducing plasma membrane cholesterol levels and changing lipid raft-dependent ACE2 and TMPRSS2 activities, these processes interfere with viral internalization by host cells (87, 110, 126). Therefore, cholesterol depletion from cellular membranes using e.g., methyl-β-cyclodextrin (MβCD) eliminates cholesterol in lipid rafts and significantly reduces clathrin-dependent endocytosis to significantly eliminate IBV, TGEV, and SARS-CoV infectivity (Figure 1A) (117, 119, 127). In addition, SARS-CoV-2 pathogenicity was significantly dependent on TMPRSS2 (128). Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19 (129). The SARS-CoV-2 Omicron variant showed less efficient replication and fusion activity when compared with the Delta variant in TMPRSS2-expressed cells (130). Omicron infection was not enhanced by TMPRSS2 but was largely mediated by the endocytic pathway. The differences in pathway entry between variants may have impacted on clinical manifestation or disease severity (130). In addition, anti-androgens target TMPRSS2 and reduce SARS-CoV-2 virus entry in lung cells (131), which may at least in part explain why men with COVID-19 have a worse prognosis when compared to women (132). SARS-CoV-2 cell entry inhibition via TMPRSS2 was facilitated by camostat, nafamostat mesylate and alpha-1 antitrypsin (133, 134). It is therefore possible that inhibiting androgen signaling by anti-androgens could reduce TMPRSS2 expression in the lung, and concomitantly reduce viral entry. For this reason, anti-androgens are proposed as treatment options for COVID-19 (135, 136).
Infectivity is also reduced by depleting cholesterol from the viral envelope as in TGEV (127). Similarly, plasma membrane cholesterol depletion is also triggered by ACE2 displacement from lipid rafts to non-raft membrane domains, thereby reducing efficient SARS-CoV cell entry (120). Previous studies reported that 27-hydroxycholesterol (27HC) accumulation in lipid rafts caused the rapid consumption of lipid raft cholesterol, interrupted cell signal transduction in lipid raft membrane microdomains, and specifically inhibited IL-6-JAK-STAT3 signaling (137, 138). It is worth emphasizing that lipid raft destruction due to cholesterol consumption may be the main reason for inhibiting extracellular signal-regulated kinase (ERK) signaling and activation inhibition (139). Since the Raf/MEK/ERK pathway is involved in the modulation of various important cellular functions, numerous DNA and RNA viruses coopt this pathway for efficient viral propagation (140). The ERK pathway is known to be modulated during PEDV infection (141). In our previous research, we reported that IBV infection activated ERK1/2 signaling and that up-regulation of the phosphatase, DUSP6 formed a negative regulation loop (142). ERK activation is necessary for PEDV and porcine deltacoronavirus (PDCoV) replication, the suppression of viral protein expression, and viral RNA transcription via ERK activation inhibition (140, 143). Also, the negative regulation of the Raf/MEK/ERK signaling pathway by the MEK inhibitor, U0126 or DUSP6 upregulation significantly impairs MHV and IBV progeny production (142, 144), respectively. However, the exact mechanism whereby ERK activity regulates the replication cycle of PEDV during infection remains unclear. Therefore, the targeted regulation of lipid raft cholesterol levels may be a host defense strategy against coronavirus infection (145).

**Host Cholesterol in Viral Fusion**

Along with binding to host cell receptors, viral envelope fusion with host cell membranes is critical in establishing successful coronavirus infection, especially for viral gene delivery into the cytoplasm. Coronaviruses enter cells by fusing directly with the cell surface or internalization via endosomal membranes (146). In general, the viral envelope contains specific cholesterol quantities; cholesterol is an important component of lipid rafts, and the fusion of viruses and host plasma membranes is affected by the ratio of membrane cholesterol to fatty acids (147). Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening revealed that cholesterol metabolism was a key host pathway promoting coronavirus (SARS-CoV-2, HCoV-229E, and HCoV-OC43) infections (84), whereas cholesterol dysregulation reduced viral invasion (82, 84, 100, 148). In addition, coronavirus enters cells either via fusion or endocytosis (149) via clathrin-mediated mechanisms in a cholesterol dependent manner (Figure 1B) (92). Cellular cholesterol homeostasis regulation, especially in endosomal compartments, exerts a significant impact on the entry stage of viral infection (108). It is because that coronavirus or coronavirus-containing MVBs via the endosomal cathepsin activate viral S protein to mediate the cytoplasmic release of viral nucleic acid, and artificially destroying the homeostasis of cholesterol in the endosomal membrane will inhibit this invasion step (91, 150). Therefore, the virus reprograms cholesterol metabolism to promote virus replication, or specific infection-induced host defense responses. Targeting cholesterol metabolism pathways in cells could be a potential target for interfering with “viral cargo”, and may be used as an intervention to inhibit coronavirus membrane fusion in the endosomes (79). Many coronaviruses, including IBV, PHEV, PEDV, and FCoV pass through endosomal compartment via MVBs to enter the cytoplasm (91–94). In a previous study, IBV membrane fusion was induced in the LE/L after 1 hour post infection (91). The accumulation of cholesterol and oxidized sterols in late endosomes and MVBs also impaired virus functions, hindered viral membrane fusion, and subsequent replication (79, 151). Therefore, the destruction of cholesterol homeostasis to block viral entry exemplifies the importance of cholesterol during viral infections (150). Cholesterol function during viral invasion was extensively studied in several coronaviruses, including SARS-CoV (120), PEDV (152), MHV (123, 153), PDCoV (154), and IBV (117, 119).

Coronavirus infections may be significantly restricted by IFN-induced transmembrane proteins (IFITMs) (155). These proteins significantly inhibit endosome membrane fusion and are driven by the viral S protein (156). IFITMs inhibit viral membrane fusion before hemifusion occurs, by reducing membrane fluidity and imparting positive spontaneous curvature to outer cell membrane leaflets (157). IFITM phosphorylation status and carboxy-terminal amino acid residues are key factors determining human coronavirus entry, including, HCoV-NL63, SARS-CoV, MERS-CoV, HCoV-OC43, and MERS-CoV (158). These functional units may pass it interacts with the virus and/or host cell components of the virus entry site to regulate the fusion of the virus envelope and cell membrane (158) The vesicle membrane-associated protein A (VAPA) and oxysterol-binding protein (OSBP) jointly regulate intracellular cholesterol balance (150). IFITM3, as a member of the IFITM protein family, hinders binding of OSBP and VAPA, which not only causes abnormal cholesterol accumulation in late endosomes, but also increases membrane hardness and inhibits viral nucleic acid release (Figure 1C) (150).

**Cholesterol Metabolism Is Involved in Coronavirus Translation/Replication**

As a positive-strand RNA virus, after internalization and uncoating, coronavirus first uses its own genomic RNA as a template to replicate and produce the polyproteins, pp1a and pp1ab via cap-dependent translation, and then via autoproteolytic cleavage, 15–16 nonstructural proteins (NSPs) (159). NSPs induce the rearrangement of cholesterol-rich lipid rafts on cell membranes, forming double-membrane vesicles (DMVs) in the cytoplasm, thereby anchoring viral replication transcription complexes (160). DMVs act as efficient replication sites for coronavirus genomic RNA and provide a safe site for viral RNA replication and translation (161). Cholesterol is also enriched in DMVs and constitutes the viral replication site of DMVs with fatty acids (80, 162). DMVs destroyed by Oxy210 (semi-synthetic oxysterol) significantly inhibit SARS-COV-2 replication in vitro (163) (Figure 1D). Thus, disruption of lipid rafts may affect viral replication and transcriptional synthesis. Recently, it was reported that intracellular cholesterol biosynthesis and transport...
systems were related to virus replication (164–166). Cellular cholesterol is derived from the biosynthesis and cellular uptake of low-density lipoprotein (167–169). U18666A is a cationic amphiphilic drug affecting cholesterol biosynthesis and intracellular transport (170). Previous studies reported that cholesterol was involved in the viral life cycle of type I FCoV infection (64), and that U18666A induced cholesterol accumulation via NPC1 dysfunction and type I FCoV replication inhibition (144, 171, 172).

Host Cholesterol May Not Be Involved in Coronavirus Assembly and Release

Afer un-coating, translation, and genome replication, virus particles assemble in the endoplasmic reticulum (ER)-Golgi intermediate compartment and are coordinated by the M protein (159, 173). For most coronaviruses, virus assembly sites contain highly active enzymes involved in the cholesterol biosynthesis pathway; these include, cholesterol-synthesizing enzyme, 3-hydroxy-3-methyl glutaryl coenzyme A reductase, and mevalonate diphospho decarboxylase (165, 174, 175). Several studies indicated that many enveloped viruses, such as human immunodeficiency virus, Dengue, Zika, and alphavirus contain cholesterol in the virion, and that viral proteins involved in virus particle assembly and budding are related to cholesterol (78, 176). Furthermore, different cholesterol levels in hosts generate different envelope cholesterol levels in aliphaviruses (177). When compared with mayaro virus particles from mosquito cells, virus particle envelopes from vertebrate cells have higher cholesterol levels (178). In terms of coronaviruses, Simons et al. found that although MVH-S protein was localized to the Golgi, that contained cholesterol and lipid rafts, the assembled and released of MVH is not associated with cholesterol (167). But, cholesterol involvement in virus assembly and budding has mainly focused on viruses budding from cell membranes, however, studies on viruses budding from intracellular membranes are rare (167). Moreover, the different functional roles of cholesterol in enveloped RNA virus stability, infectivity, and assembly are not entirely clear (177, 179). Therefore, coronavirus assembly and budding may not necessarily use cholesterol on Golgi membranes, thus specific mechanisms require further study.

Cholesterol Metabolizing Enzymes and Metabolites Combat Coronavirus Infectivity

Coronavirus infection induces host cells to alter the expression of certain cholesterol metabolizing enzymes and metabolites which may exert antiviral effects (Figure 2A) (77). Indeed, both 25-hydroxycholesterol (25HC) and 27-hydroxycholesterol (27HC) are physiologically produced by the enzymatic oxidation of cholesterol and may be used to inhibit enveloped and non-enveloped human viruses (183, 184) and highly pathogenic viruses, including Zika (185), mammalian reovirus (186), Lassa virus (187), encephalomyocarditis virus (188), porcine reproductive and respiratory syndrome virus (189). A recent study reported that the 25HC treatment of mice infected with SARS-CoV-2 significantly reduced virus numbers in the lungs and trachea (148). On the one hand, cholesterol is transformed into 25HC by Cholesterol 25-Hydroxylase (CH25H). By obstructing membrane fusion, 25HC exhibits extensive anti-coronavirus activity (125, 184). Similarly, the internalization of 25HC aggregates in late endosomes may inhibit spike protein-catalyzed membrane fusion of SARS-CoV-2 by blocking cholesterol export (124); however, CH25H consumes available cholesterol on the plasma membrane to suppress virus-cell fusion (125). These data indicate that membrane-modifying oxysterols are possible antiviral therapeutics, thereby inhibiting SARS-CoV-2 and other coronaviruses (Figure 1A) (153). However, it is possible to obstruct PDGfV proliferation using CH25H which acts as a host restriction factor, but this inhibition is not entirely dependent on its enzymatic activity (190). The junction adhesion molecule-A and the cation independent isoform of the mannose-6-phosphate receptor are two key replication molecules common to all viruses that use adhesion molecules and the endosomal pathway to enter and diffuse target cells. Both molecules are downregulated by 25HC and 27HC (191).

Previous studies suggested that SARS-CoV-2 propagation in cultured cells was inhibited by various cholesterol molecules, including natural oxysterols, 7-ketocholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 27HC (Figures 2A-e, c) (163). At effective concentrations, 25HC, 7-dehydrocholesterol (7DHC), and 27HC were non-toxic natural products, with potentially curative applications for emerging virus infections, such as SARS-CoV-2 (192), human immunodeficiency virus, Ebola virus, Nipah virus, Rift Valley fever virus, and Zika (153).

The Sterol Metabolic Network Participates in Host-Immune Responses

All coronaviruses have a similar infection mechanism, which successfully manipulates host cell functions. One strategy to suppress the host innate immune response to evade antiviral responses, is shielding RNA intermediates in replication organelles (193, 194). In fact, coronaviruses with +RNA genomes, which duplicate solely in the cytoplasmic matrix, and modify the inner membranes of cells to form virus duplication bases, also known as “replication factories” or “replication organelles”. While varying in morphology and membrane composition, these structures appear to centralize viral replication machinery, intermediates, and products in membrane-bound vesicles or invaginations, and are beyond the reach of innate immune sensors in the cytosol. Thus, viral infection outcomes are determined by metabolic interactions between hosts and viruses (195). Cholesterol is a crucial component of cell membranes and lipid rafts. Cholesterol metabolism contributes to the formation of immune synapses and downstream signal transmission (196). The host’s defenses against virus infection requires IFN-mediated cholesterol biosynthesis and the formation of immune synapses, and also host innate immune metabolic regulators as potential antiviral strategies (197).

Two molecules, sterol regulatory element-binding protein-2 (SREBP-2) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), have significant roles in the cholesterol biosynthetic pathway; SREBP-2 is the master transcriptional regulator of cholesterol biosynthesis (Figures 2B-e, g) and HMGCR is a rate-
limiting enzyme for cholesterol synthesis (198). SREBP-2 cleavage and HMGCR degradation are two major feedback regulatory mechanisms governing cholesterol biosynthesis (Figures 2A-a) (58). Recently, the sterol metabolic network was shown to participate in interferon (IFN) antiviral responses (58). (A) HMG-CoA reductase regulates cholesterol biosynthesis and is targeted by statins. (b, c, d) The sterol metabolic network participates in interferon (IFN) antiviral responses. (e, f) SARS-CoV-2 propagation in cultured cells is inhibited by various cholesterol molecules and semi-synthetic oxysterols. The detailed steps of the cholesterol synthesis pathway can be found in (180–182). (B) Cholesterol metabolism reprogramming and antiviral responses after viral infection. (a) Cholesterol promotes pathological syncytial formation during SARS-CoV-2 infection. (b) Serum TC, TG, and non-esterified polyunsaturated fatty acid levels are remodelled in COVID-19 patients. (c, d) SARS-CoV-2 infection increases glucose entry into the TCA cycle via increased pyruvate carboxylase expression and reduced oxidative glutamine metabolism, while maintaining reductive carboxylation. (f) SREBP-dependent lipidomic reprogramming is a broad-spectrum antiviral target, AM580 strongly inhibits coronavirus replication by interacting with SREBP-2. (e, h, g, i, j) COVID-19-activated SREBP-2 disturbs cholesterol biosynthesis, leading to a cytokine storm. Importantly, SREBP-2 activity is regulated by crosstalk between cholesterol consumption and NF-κB expression via several inflammatory response processes induced by SARS-CoV-2 infection. Red arrows represent upregulation and blue arrows represent downregulation. Acetyl-CoA, Acetyl-Coenzyme A; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; EBP, Δ(7)-isomerase; DHCR24, 3-β-hydroxy-3-methylglutaryl-coenzyme A; 25HC, 25-hydroxycholesterol; 27HC, 27-hydroxycholesterol; IFN, Interferon-α, IFNG, Interferon-γ; TC, Total cholesterol; HDL, Low-density lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol; TG, Triglyceride; ATP, Adenosine triphosphate; SREBP-2, Sterol regulatory element-binding protein 2; AM80, a selective PPARα agonist; HMGCR, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase; NF-κB, Nuclear transcription factor-KB.

FIGURE 2 | Overview of mevalonate pathway and coronavirus infection. (A) Cholesterol metabolizing enzymes and metabolites act against viral infectivity. Red type represents cholesterol metabolizing enzymes or corresponding natural products which may be used as drug targets or directly to exert antiviral effects. (a) HMG-CoA reductase regulates cholesterol biosynthesis and is targeted by statins. (b, c, d) The sterol metabolic network participates in interferon (IFN) antiviral responses. (e, f) SARS-CoV-2 propagation in cultured cells is inhibited by various cholesterol molecules and semi-synthetic oxysterols. The detailed steps of the cholesterol synthesis pathway can be found in (180–182). (B) Cholesterol metabolism reprogramming and antiviral responses after viral infection. (a) Cholesterol promotes pathological syncytial formation during SARS-CoV-2 infection. (b) Serum TC, TG, and non-esterified polyunsaturated fatty acid levels are remodelled in COVID-19 patients. (c, d) SARS-CoV-2 infection increases glucose entry into the TCA cycle via increased pyruvate carboxylase expression and reduced oxidative glutamine metabolism, while maintaining reductive carboxylation. (f) SREBP-dependent lipidomic reprogramming is a broad-spectrum antiviral target, AM580 strongly inhibits coronavirus replication by interacting with SREBP-2. (e, h, g, i, j) COVID-19-activated SREBP-2 disturbs cholesterol biosynthesis, leading to a cytokine storm. Importantly, SREBP-2 activity is regulated by crosstalk between cholesterol consumption and NF-κB expression via several inflammatory response processes induced by SARS-CoV-2 infection. Red arrows represent upregulation and blue arrows represent downregulation. Acetyl-CoA, Acetyl-Coenzyme A; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; EBP, Δ(7)-isomerase; DHCR24, 3-β-hydroxy-3-methylglutaryl-coenzyme A; 25HC, 25-hydroxycholesterol; 27HC, 27-hydroxycholesterol; IFN, Interferon-α, IFNG, Interferon-γ; TC, Total cholesterol; HDL, Low-density lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol; TG, Triglyceride; ATP, Adenosine triphosphate; SREBP-2, Sterol regulatory element-binding protein 2; AM80, a selective PPARα agonist; HMGCR, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase; NF-κB, Nuclear transcription factor-KB.
which were essential for the stabilization of T regulatory cells (201). Cholesterol is required for SARS-CoV-2 to form pathological syncytia which is believed to help replicate and evade host immune responses (67). For example, cholesterol biosynthesis pathways are affected by SARS-CoV which regulate levels of SREBP2, S1 protein, peroxisome proliferators-activated receptors γ (PPARγ), diacylglycerol acyltransferase-1 or cholesterol efflux regulator protein (203–205). COVID-19-activated SREBP2 disturbs cholesterol biosynthesis (Figures 2B-e), leading to a cytokine storm (50) (Figures 2 B-j). Importantly, SREBP-2 activity is regulated by crosstalk between cholesterol consumption and nuclear factor-κB (NF-κB) expression from various inflammatory response processes induced by SARS-CoV-2 infection (Figures 2B-h) (50). In addition, a metabolic configuration is induced by SREBPs where glucose is metabolized via the citrate malate shuttle, thus enabling natural killer cell growth, proliferation, and function (206). Therefore, SREBP-dependent lipidomic reprogramming may be viewed as a broad-spectrum antiviral target (203). 25HC exerts inflammatory properties and significantly attenuates proteolytic processing of SREBP2 (Figures 2A-c), thereby inhibiting the isoprenoid branch of the mevalonate pathway (207). 25HC also amplifies inflammatory signals (207), with growing evidence suggesting it has a broad impact on innate and adaptive immunity (195, 208–213), including antiviral immunity, inflammation, and antibody class switching (214). In addition, lung-selective 25HC nano-therapeutics may function as inhibitors of COVID-19-mediated cytokine storms (215). IFN-β production may be regulated by targeting the 7-dehydrocholesterol reductase (DHCR7) and adding 7-dehydrocholesterol (7-DHC), an intermediate natural product in the cholesterol metabolism pathway (77) (Figures 2A-b). Moreover, it is possible to enhance anti-viral immunity by promoting serine/threonine kinase 3 (AKT3) activation (77); a positive feedback loop is formed via type I IFN signaling and 7DHCAccumulation to amplify innate immune responses and control viral infection by activating AKT3. Also, the emergence of highly pathogenic viruses may be inhibited by DHCR7 inhibitors and 7-DHC (216). York et al. suggested that a reduction in cholesterol biosynthesis was a key event in inducing antiviral responses in virus-infected cells (172) and that decreased cholesterol biosynthesis facilitated anti-viral signaling by the stimulator of interferon gene (STING) in the ER (Figures 2A-d) (216). Although cholesterol is a crucial component of immune cell membranes, cholesterol accumulation in lymphoid organs promoted T cell priming and stimulated the production of the B cell growth factors, Baf and April (217). Ito et al. (2016) reported that defects in cholesterol metabolism in CD11c+ immune cells resulted in impaired antigen presentation and ultimately autoimmunity disease (218). Excessive cholesterol may exert immune dysfunction and promote excessive pulmonary and systemic inflammatory responses (219).

**Cholesterol-Modifying Drugs Inhibit Coronavirus Replication**

Recently, several commonly prescribed medications were shown to interfere with sterol biosynthesis, including haloperidol, aripiprazole, cariprazine, fluoxetine, trazodone, and amiadaroine (220). Cholesterol-modifying drugs exert anti-viral roles by reducing the absorption or synthesis of systemic cholesterol or directly changing cholesterol levels in target cell membranes (219) (Figure 1A). It is possible to alter the SARS-CoV-2 cycle *in vitro* and *in vivo* using various cholesterol-modifying drugs (e.g., AM580 is a selective retinoic acid receptor alpha (RAR-α) agonist, fibrates, and statins) which hinder fatty acid and cholesterol synthesis (Figure 1E) (221). In fact, cholesterol-binding agents, including statins or MβCD, affect cholesterol and destroy lipid rafts, thereby damaging coronavirus adhesion and binding properties (119, 222). Moreover, these compounds also block key downstream virus infectivity molecules, reduce proinflammatory tumor necrosis factor-α (TNF-α) and IL-6 levels, and/or affect autophagic processes in viral replication and clearance (222). It is worth noting that cholesterol, fatty acids, cytosolic phospholipase A2α (cPLA2α), and fatty acid synthase contribute to SARS-CoV-2 DMV formation (204, 223). For example, fenofibrate reduces triglyceride and low-density lipoprotein cholesterol levels inhibit SARS-CoV-2 replication and pathogenesis by affecting lipid metabolism pathways in the lung cells of patients with COVID-19 (224). AM580 is a retinoid derivative which interacts with N-terminal SREBP to block lipogenic transactivation (203). Statins reduce intra- and extra-cellular cholesterol by targeting HMGCR (Figures 2A-a) (225, 226), thereby affecting viral infection, immunity, and inflammation (219). Statins may also limit inflammation by altering HMGCR mediators in the cholesterol biosynthesis pathway (227, 228). These anti-inflammatory properties are considered statin’s core protective effects in cardiovascular disease, in addition to lowering cholesterol levels (225). Wang et al. suggested that high cholesterol levels increased entry of pseudotyped SARS-CoV-2 and the infection of virus particles, and more of the receptor ACE2 can be recruited to the internalization site (229). Statins ability to decrease lipids, enhance protective immune responses, and exert anti-inflammatory properties are beneficial during SARS-CoV-2 infections (219). Statin therapy was previously reported to increase blood clearance rates in chronic HCV infections and reduce mortality and intubation requirements during influenza infection (118). Statins, especially pitavastatin, may significantly inhibit activity of SARS-CoV-2’s main protease, Mpro, which has a greater binding energy than proteases or polymerase inhibitors (230). Decreasing cellular cholesterol may also trigger the intake of more cholesterol from the blood, reducing serum HDL-cholesterol (HDL-C) and LDL-C levels. As cholesterol-lowering drugs, statins are widely used in cardiovascular and metabolic diseases (231, 232). They inhibit inflammation by reducing cholesterol and phospholipid deposition in blood vessels. Thus, anti-inflammatory molecules provide protective effects in cardiovascular diseases, and do not just lower cholesterol (225).

**Cholesterol as a Potential Marker for Monitoring COVID-19**

SARS-CoV-2 infection reshapes cholesterol metabolism via gene activation and increased host metabolism activity (23) (Figure 2B). Briefly, SARS-CoV-2 infection disturbs cholesterol biosynthesis by activating SREBP-2 and affecting glucose or glutamine metabolism (50, 233) (Figures 2B-e, c, d). Clinical data has also indicated that lipid disorders may facilitate increased COVID-19 mediated...
pathogenicity, therefore lowering cholesterol levels may inhibit SARS-CoV-2 replication and viral loads in patients (51, 65). When compared with healthy individuals, patients with dyslipidemia-related diseases are more likely to be infected by SARS-CoV-2 (234, 235). Also, SARS-CoV-2 infection caused some COVID-19 patients to have lower serum cholesterol levels (e.g., 27HC, total cholesterol, high density lipoprotein cholesterol, and low-density lipoprotein cholesterol), while triglyceride and non-esterified polyunsaturated fatty acid levels were up-regulated (Figures 2B-b) (27, 236–238). In particular, decreased serum HDL-C levels are positively correlated with COVID-19 infection severity (239). As infection worsens, serum TC and HDL are lowered, but upon recovery, cholesterol levels return to normal (65, 239–243). This may be due to SARS-CoV-2 S proteins affecting HDL functions by removing lipids from HDL and remodeling its composition/structure (243), potentially affecting virus clearance in infected patients (244). Thus, serum cholesterol and lipoprotein marker monitoring may have an important clinical value for COVID-19 risk prediction (115). Increased triglyceride/HDL-C ratios may be useful for the early identification of patients with high risk and poor outcomes (245, 246). Moreover, in patients with severe disease, significantly elevated serum HDL levels are associated with favorable outcomes (112). HDL-C levels decrease significantly in critically ill COVID-19 patients and are negatively correlated with C-reactive protein and IL-6 levels, however lymphocyte levels are increased with increased HDL-C levels, which positively correlate with the COVID-19 severity (247). Therefore, LDL-C levels may be used as predictors of COVID-19 progression and risk assessment (248).

SREBP is a membrane junction protein attached to the ER and nuclear envelope (249); it regulates the effective synthesis of fat and cholesterol and plays important roles in maintaining energy homeostasis (Figures 2B-g) (250, 251). The SREBP protein family regulate lipid cholesterol and fatty acid gene expression via mitogen-activated protein kinase (MAPK) signaling (252). A recent study reported that SREBP-2 C-terminal fragment was detected for the first time in the blood of patients with COVID-19. Based on data from clinical samples, SREBP-2 C-term was suggested as a reference indicator to assess disease severity after SARS-CoV-2 infection (50). SREBP-2-dependent lipidomic reprogramming is a broad-spectrum antiviral target, with SREBP-2 activation correlating with COVID-19-induced cytokine storm activation (235). AM580 strongly inhibits coronavirus replication by interacting with SREBP-2 (203, 204).

CONCLUSIONS

Viruses are intracellular parasitic pathogens. They exploit host nutrients and metabolites to accommodate their survival and are highly adaptable molecules in escaping host antiviral responses. Therefore, interventions in host specific metabolic pathways could become potential antiviral targets (80, 203, 205, 253). Potential cholesterol-modifying drugs exert broad-spectrum antiviral effects by inhibiting activities of key rate-limiting enzymes in the mevalonate pathway, and also SREBP proteins which regulate host cholesterol homeostasis, thereby affecting coronavirus entry, membrane fusion, and pathological syncytia formation (204). Thus, cholesterol metabolism disorder is a double-edged sword; it affects the normal physiological functions of cells, however, weaponizing cholesterol dysregulation in local cell environments such as lipid rafts or endosomes could inhibit coronavirus replication. Therefore, the development of selective cholesterol-modifying drugs targeting key cellular components such as lipid rafts and endosomes in infected cells could be a promising antiviral strategy for the early stages of coronavirus infection.

AUTHOR CONTRIBUTIONS

CD and XQ conceived the review concept and drafted the article. JD and HW wrote the original draft and prepared figures. YL, LT, YS, CS, and WL edited and reviewed the manuscript. All authors read and agreed to the final published version of the manuscript.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (Grant No. 32030108), the Foundation of Key Laboratory of Veterinary Biotechnology (No. shklab202001), and Natural Science Foundation of Shanghai (Grant No. 21ZR1476800 & 20ZR1469400). We thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript. Figures were drafted using BioRender.com. Adapted from “ZIKV Infection Cycle” and “Mechanisms behind the induction of trained Immunity” by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates.

REFERENCES

1. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et al. Identification of a Novel Coronavirus in Patients With Severe Acute Respiratory Syndrome. N Engl J Med (2003) 348(20):1967–76. doi: 10.1056/NEJMoat030747
2. Isaacs D, Flowers D, Clarke JR, Valman HB, Macnaughton MR. Epidemiology of Coronavirus Infections. Arch Dis Childhood (1983) 58(7):500–3. doi: 10.1136/adc.58.7.500
3. Yang D, Leibowitz JL. The Structure and Functions of Coronavirus Genomic 3’ End. Virus Res (2015) 206:120–33. doi: 10.1016/j.virusres.2015.02.025
4. Cui J, Li F, Shi Z-L. Origin and Evolution of Pathogenic Coronaviruses. Nat Rev Microbiol (2019) 17(3):181–92. doi: 10.1038/s41579-018-0118-9
5. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From Sars to Mers, Trusting Coronaviruses Into the Spotlight. Viruses (2019) 11(1):59. doi: 10.3390/v11010059
6. Chan JF-W, Lau SK-P, Woo PC-Y. The Emerging Novel Middle East Respiratory Syndrome Coronavirus: The ‘Knowns’ and ‘Unknowns’. J Formos Med Assoc (2013) 112(7):372–81. doi: 10.1016/j.jfma.2013.05.010
7. Belouzard S, Millet JK, Licistra BN, Whittaker GR. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses (2012) 4(6):1011–33. doi: 10.3390/v4061011
8. Kirtipal N, Bharadwaj S, Kang SG. From Sars to Sars-Cov-2, Insights on Structure, Pathogenicity and Immunity Aspects of Pandemic Human Coronaviruses. Infect Genet Evol (2020) 85:104502. doi: 10.1016/j.meegid.2020.104502
9. Wacharapluesadee S, Tan CW, Maneenorn P, Duengkae P, Zhu F, Joyjinda Y, et al. Evidence for Sars-CoV-2 Related Coronaviruses Circulating in Bats and Pangolins in Southeast Asia. *Nat Commun* (2021) 12(1):972. doi: 10.1038/s41467-021-21204-1

10. Tortorici MA, Veesler D. Structural Insights Into Coronavirus Entry. *Adv Virus Res* (2019) 105:93–116. doi: 10.1016/bs.avir.2019.08.002

11. Gouill MA, Puechmaire SJ, Gonzalez J-P, Teeling E, Kittayapong P, Manuguerra J-C. Sars-Coronavirus Ancestor's Footprint in South-East Asian Bat Colonies and the Refugee Theory. *Infect Genet Evol* (2011) 11(7):1690–702. doi: 10.1016/j.meegid.2011.06.021

12. Yang Y-L, Qin P, Wang B, Liu Y, Xu G-H, Peng L, et al. Broad Cross-Species Infection of Cultured Cells by Bat HKU2-Related Swine Acute Diarrhea Syndrome Coronavirus and Identification of Its Replication in Murine Dendritic Cells Highlight Its Potential for Diverse Interspecies Transmission. *J Virol* (2019) 93(24):e01448-19. doi: 10.1128/JVI.01448-19

13. Zhou P, Fan H, Lan T, Yang X-L, Shi W-F, Zhang W, et al. Fatal Swine Acute Diarrhoea Syndrome Caused by an H22-Related Coronavirus of Bat Origin. *Nature* (2018) 556(7705):235–8. doi: 10.1038/s41586-018-01010-9

14. Li F. Structural Analysis of Major Species Barriers Between Humans and Palm Pangolins in Southeast Asia. *J Hepatol* (2020) 72(5):877–83. doi: 10.1016/j.jhep.2020.09.031

15. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus (SARS-CoV-2) Outbreak in Wuhan, China. *N Engl J Med* (2020) 382(10):977–83. doi: 10.1056/NEJMc2001017

16. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus Biology and Replication: Implications for Sars-CoV-2. *Nat Rev Microbiol* (2021) 19(3):155–70. doi: 10.1038/s41579-020-00468-6

17. Asselah T, Duranteau D, Pasamnt E, Lau G, Schinazi RF. Covid-19: Discovery, Translational Signatures in Human Lung Epithelial Cells That Promote Lung Fibrosis. *Respir Res* (2020) 21(1):182. doi: 10.1186/s12931-020-01445-6

18. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of Ferrets, Cats, Dogs, and Other Domesticated Animals to Sars-CoV-2. *Science* (2020) 368(6494):1016–20. doi: 10.1126/science.abf7015

19. Azavedo RB, Botelho BG, JV Gordon H, Ferreira LV, Lianqi X, et al. Covid-19 and the Cardiovascular System: A Comprehensive Review. *J Hum Hypertens* (2021) 35(1):1–11. doi: 10.1038/s41371-020-0387-4

20. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for Covid-19: An Overview. *Crit Care* (2021) 66(2):237. doi: 10.1186/s13054-021-03662-x

21. Harrington D, Kele B, Pereira S, Couto-Parada X, Riddell A, Forbes S, et al. Confirmed Reinfection With Sars-CoV-2 Variant Voc-202012/01. *Clin Infect Dis* (2021) 73(10):1946–7. doi: 10.1093/cid/ciaa014

22. Sheikh A, McMenamin J, Taylor B, Robertson C. Sars-CoV-2 Delta Voc in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. *Lancet* (2021) 397(10293):2461–2. doi: 10.1016/S0140-6736(21)01358-1

23. Hartleeb J, Li Y, Zhang H. Emerging Sars-CoV-2 Variants of Concern and Potential Intervention Approaches. *Crit Care* (2021) 25(1):244. doi: 10.1186/s13054-021-03662-x

24. Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. Sars-CoV-2 Binds to Human Ace2 More Strongly Than Does Sars-CoV. *J Phys Chem B* (2020) 124(34):7336–47. doi: 10.1021/acs.jpcb.0c04511

25. Rajendran K, Li Y, Zhang H. Emerging Sars-CoV-2 Variants of Concern and Potential Intervention Approaches. *Crit Care* (2021) 25(1):244. doi: 10.1186/s13054-021-03662-x

26. Sharun K, Dhama K, Pawde AM, Gorta M. Covid-19 in Real Time. *Int J Environ Res Public Health* (2020) 17(7):2323. doi: 10.3390/ijerph17072323

27. Rezaei A, Neshat S, Heshmat-Ghadhari J. Alterations of Lipid Profiles during Covid-19: A Narrative Review. *Carr Probl Cardiol* (2021) 47(3):100907. doi: 10.1016/j.cpcardiol.2021.100907

28. Dong E, Du H, Gardner LM. An Interactive Web-Based Dashboard to Track Covid-19 in Real Time. *Lancet Infect Dis* (2020) 20(5):533–4. doi: 10.1016/S1473-3099(20)30129-1

29. Kumar S, Singh B, Kumari P, Kumar PV, Agnihotri G, Khan S, et al. Identification of Multipotent Drugs for Covid-19 Therapeutics With the Evaluation of Their Sars-CoV2 Inhibitory Activity. *Comput Struct Biotechnol J* (2019) 17:1998–2017. doi: 10.1016/j.csbj.2021.04.014

30. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for Covid-19. *AAAPS J* (2021) 23(1):14. doi: 10.1208/s12248-020-00332-2

31. Nguyen HL, Lan PD, Thai NQ, Nisles DA, O’Brien EP, Li MS. Does Sars-CoV-2 Bind to Human Ace2 More Strongly Than Does Sars-CoV? *J Phys Chem B* (2020) 124(34):7336–47. doi: 10.1021/acs.jpcb.0c04511

32. Khateeb J, Li Y, Zhang H. Emerging Sars-CoV-2 Variants of Concern and Potential Intervention Approaches. *Crit Care* (2021) 25(1):244. doi: 10.1186/s13054-021-03662-x

33. Dong E, Du H, Gardner LM. An Interactive Web-Based Dashboard to Track Covid-19 in Real Time. *Lancet Infect Dis* (2020) 20(5):533–4. doi: 10.1016/S1473-3099(20)30129-1

34. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. Covid-19 in People With Diabetes: Understanding the Reasons for Worse Outcomes. *Lancet Diabetes Endocrinol* (2020) 8(9):782–92. doi: 10.1016/S2213-8587(20)30238-2
58. Luo J, Yang H, Song B-L. Mechanisms and Regulation Of Cholesterol Homeostasis. *J Lipid Res* (2021) 62:100061. doi: 10.1194/jlr.R120000851

59. Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, et al. Lipidome Profiling of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Virol* (2021) 95(1):92. doi: 10.1128/JVI.00686-20

60. Heaton NS, Randall G. Multifaceted Roles for Lipids in Viral Infection. *Trends Microbiol* (2011) 19(7):368–75. doi: 10.1016/j.timi.2011.03.007

61. Del Campo JA, Romero-Gómez M. Modulation of Host Lipid Metabolism by Hepatitis C Virus: Role of New Therapies. *World J Gastroenterol* (2015) 21(38):10776–82. doi: 10.3748/wjg.v21.i38.10776

62. Lange PT, Lagunoff M, Tarakanova VL. Chewing the Fat: The Contested Ability of DNA Viruses to Hijack Cellular Lipid Metabolism. *Viruses* (2019) 11(2):119. doi: 10.3390/v11020119

63. Cheng K, Riva L, Sinha S, Pal LR, Nair NU, Martin-Sanchez L, et al. Genome-Scale Metabolic Modeling Reveals Sars-CoV-2-Induced Host Metabolic Reprogramming and Identiﬁcational Antiviral Targets. *bioRxiv* (2021). doi: 10.1101/2021.01.27.428543

64. Balgoma D, Gil-de-Gomez L, Montero O. Lipidomics Issues on Human Positive Sars Virus Infection: An Update. *Metabolites* (2020) 10(9):356. doi: 10.3390/metabo10090356

65. Luquain-Costaz C, Rabia M, Hullin-Matsuda F, Delton I. Bis Lipids: A Promising Class of Lipids for Antiviral Therapy. *Front Cell Infect Microbiol* (2020) 10:152. doi: 10.3389/fcimb.2020.01030

66. Taylor MP, Koyuncu OO, Enquist LW. Subversion of the Actin Cytoskeleton during Viral Infection: The Beginning. *Curr Opin Virol* (2019) 33:1–8. doi: 10.1016/j.coviro.2019.01.004

67. Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, et al. Sars-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation. *Elife* (2021) 10:e56962. doi: 10.7554/eLife.56962

68. Thorp EB, Gallagher TM. Requirements for Ceacam1 and Cholesterol during Mouse Coronavirus Cell Entry. *J Virol* (2004) 78(2):2682–92. doi: 10.1128/JVI.178.2.2682-2692.2004

69. Heaton NS, Randall G. Multi-Dimensional Analysis of Lipids in Viral Infection. *Trends Microbiol* (2011) 19(7):368–75. doi: 10.1016/j.timi.2011.03.007
90. Matsuyma S, Uijike M, Morikawa S, Tashiro M, Taguchi F. Protease-Mediated Enhancement of Severe Acute Respiratory Syndrome Coronavirus Infection. *Proc Natl Acad Sci USA* (2005) 102(35):12543–7. doi: 10.1073/pnas.0503203102

91. Wang H, Yuan X, Sun Y, Mao X, Meng C, Tan L, et al. Infectious Bronchitis Virus Entry Mainly Depends on Clathrin Mediated Endocytosis and Requires Classical Endosomal/Lysosomal System. *Virology* (2019) 528:118–36. doi: 10.1016/j.virol.2018.12.012

92. Li Z, Zhao K, Lan Y, Lv X, Hu S, Guan J, et al. Porcine Hemagglutinating Encephalomyelitis Virus Enters Neuro-2a Cells Via Clathrin-Mediated Endocytosis in a Rab5-, Cholesterol-, and Ph-Dependent Manner. *J Virol* (2017) 91(23):e01083-17. doi: 10.1128/JVI.01083-17

93. Wei X, She G, Wu T, Xue C, Cao Y. Pedv Enters Cells Through Clathrin-, Caveolae-, and Lipid Raft-Mediated Endocytosis and Traffics Via the Endo- Lysosome Pathway. *Vet Res* (2020) 51(1):10. doi: 10.1186/s13576-020-01373-7

94. Takano T, Wakayama Y, Doki T. Endocytic Pathway of Feline Coronavirus Endocytosis in a Rab5-, Cholesterol-, and Ph-Dependent Manner. *Frontiers in Immunology* www.frontiersin.org April 2022 | Volume 13 | Article 79126

95. Perlman S, Netland J. Coronaviruses Post-Sars: Update on Replication and Pathogenesis. *Rev Virol* (2021) 12(1):961. doi: 10.1038/s41467-021-21213-4

96. Morgan PK, Fang L, Lancaster GI, Murphy AJ. Hematopoiesis Is Regulated by Cholesterol-Dependent Entolysosomal Host-Sars-CoV-2 Interface by Naturally Activated Neutrophils. *Proc Natl Acad Sci USA* (2020) 117(50):32105–10. doi: 10.1073/pnas.20068528

97. Schloder S, Brunotte L, Gereke V, Korshals N, Gerke V, et al. Targeting the Endolysosomal Host-Sars-CoV-2 Interface by Clinically Licensed Functional Inhibitors of Acidic Sphingomyelinase (Fasma) Including the Antidepressant Fluoxetine. *Emerg Microbes Infect* (2020) 9(1):2245–55. doi: 10.1002/emmicro.21751.2020.829082

98. Wei C, Wang Z, Yang F, Cao Y, Zhong H. Cholesterol Metabolism–Impact for Sars-CoV-2 Infection Progression, Entry, and Antiviral Therapies. (2020) doi: 10.1101/2020.04.16.20068528

99. Wei X, She G, Wu T, Xue C, Cao Y. Pedv Enters Cells Through Clathrin-, Caveolae-, and Lipid Raft-Mediated Endocytosis and Traffics Via the Endo- Lysosome Pathway. *Vet Res* (2020) 51(1):10. doi: 10.1186/s13576-020-01373-7

100. Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, et al. A Genome-Wide Crispr Stabilized Coronavirus Spikes Are Resistant to Conformational Changes (2019) 8(4):300. doi: 10.3390/pathogens8040300

101. Li G-M, Li Y-G, Yamate M, Li S-M, Ikuta K. Lipid Rafts Play an Important Role in the Early Stage of Severe Acute Respiratory Syndrome Coronavirus Life Cycle. *Microbes Infect* (2007) 9(1):96–102. doi: 10.1016/j.micinf.2006.10.015

102. D’Souza RS, et al. Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Spike Protein Complexed With Receptor Reveals Mechanism for Viral Entry. *J Virol* (2008) 82(12):1391. doi: 10.1128/JVI.0170123. doi: 10.1371/journal.pone.0170123

103. Lu Y, Liu DX, Tam JP. Lipid Rafts Are Involved in Sars-CoV Entry Into Vero E6 Cells. *Biochem Biophys Res Commun* (2008) 369(2):344–9. doi: 10.1016/j.jbc.2008.02.023

104. Glende J, Schwengwag- Wessels C, Al-Falah M, Pfeiffer A, Xu X, Deng H, et al. Importance of Cholesterol-Rich Membrane Microdomains in the Interaction of the S Protein of Sars-CoV-2 With the Cellular Receptor Angiotensin-Converting Enzyme 2. *Virology* (2008) 381(2):215–27. doi: 10.1016/j.virol.2008.06.028

105. Yin J, Glende J, Schwengwag- Wessels C, Enjuanes L, Herrler G, Ren X. Cholesterol Is Important for a Post-Adsorption Step in the Entry Process of Transmissible Gastroenteritis Virus. *Antiviral Res* (2010) 83(3):311–6. doi: 10.1016/j.antiviral.2010.01.002

106. Choi KS, Aizaki H, Lai MMC. Murine Coronavirus Requires Lipid Rafts for Viral Entry and Cell-Culture Fusion But Not for Virus Release. *J Virol* (2005) 79(15):9862–71. doi: 10.1128/JVI.79.15.9862-9871.2005

107. Zang R, Case JB, Yutuc E, Ma X, Shen S, Gomez Castro MF, et al. Cholesterol 25-Hydroxylase Suppresses Sars-CoV-2 Replication by Blocking Membrane Fusion. *Proc Natl Acad Sci USA* (2020) 117(50):32105–13. doi: 10.1073/pnas.2012197117

108. Ren X, Glende J, Schwengwag- Wessels C, Enjuanes L, Herrler G, Ren X. Cholesterol Is Important for a Post-Adsorption Step in the Entry Process of Transmissible Gastroenteritis Virus. *J Virol* (2021) 93(5):e016057. doi: 10.1128/jvi..2020.016057

109. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhao T, et al. Structural Basis for the Potential Juncture Between Sars-CoV-2 Infectivity and Niemann-Pick Disease Type C. *Sci Adv* (2020) 6(7):eabb2762

110. Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The Lysosome: A Potential Juncture Between Sars-CoV-2 Infectivity and Niemann-Pick Disease Type C With Therapeutic Implications. *FASEB J* (2020) 34 (6):7253–64. doi: 10.1096/fj.202000654R

111. Ren X, Glende J, Schwengwag- Wessels C, Herrler G. Importance of Cholesterol for Infection of Cells by Transmissible Gastroenteritis Virus. *Proc Natl Acad Sci USA* (2008) 105(22):8308–13. doi: 10.1073/pnas.0801104105

112. Abbasi AZ, Kiyani DA, Hamid SM, Salim M, Fahim A, Jalal N. Spiking Dependence of Sars-CoV-2 Pathogenicity on Tmprss2. *J Med Virol* (2021) 93(7):4205–18. doi: 10.1002/jmv.26437
205. Dias SSG, Soares VC, Ferreira AC, Sacramento CQ, Fintelman-Rodrigues N, Temerzo JR, et al. Lipid Droplets Fuel Sars-CoV-2 Replication and Production of Inflammatory Mediators. PLoS Pathog (2020) 16(12): e1009127. doi: 10.1371/journal.ppat.1009127

206. Assmann N, O’Brien KL, Donnelly RP, Dyck L, Zaiat-Bittencourt V, Loftus RM, et al. Srebp-Controlled Glucose Metabolism Is Essential for Nk Cell Functional Responses. Nat Immunol (2017) 18(11):1197–206. doi: 10.1038/ni.3838

207. Gold ES, Diercks AH, Podmlysky I, Podymimogn RL, Askovich PS, Treuting PM, et al. 25-Hydroxycholesterol Acts as an Amplifier of Inflammatory Signaling. Proc Natl Acad Sci USA (2014) 111(29):10666–71. doi: 10.1073/pnas.1404271111

208. Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in Innate and Adaptive Immunity. Nat Rev Immunol (2014) 14(11):731–43. doi: 10.1038/nri3755

209. Wong MY, Lewis M, Doherty JJ, Shi Y, Cashiak AG, Amelianchik A, et al. 25-Hydroxycholesterol Amplifies Microglial 2-1β Production in an Apoe Isoform-Dependent Manner. J Neuroinflamm (2020) 17(1):192. doi: 10.1186/s12974-020-01869-3

210. Madenspacher JH, Morrell ED, Gowdy KM, McDonald JG, Thompson BM, Muse G, et al. Cholesterol 25-Hydroxylase Promotes Effectorcyosis and Resolution of Lung Inflammation. JCI Insight (2020) 5(11):e137789. doi: 10.1172/jci.insight.137789

211. Iannone J, Kammoun H, Garcia-Cassani B, Chesne J, Parigi SM, Jacob J-M, et al. Oysterol Sensing Through the Receptor Grp183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. Immunity (2018) 48(1):120–32.e8. doi: 10.1016/j.immuni.2017.11.020

212. Koarai A, Yanagisawa S, Sugihara H, Ichikawa T, Kikuchi T, Furukawa K, et al. 25-Hydroxycholesterol Enhances Cytokine Release and Toll-Like Receptor 3 Response in Airway Epithelial Cells. Respir Res (2012) 13:63. doi: 10.1186/1466-9351-13-63

213. Pohkarel SM, Shak🔥 NK, Gc JB, Colburn ZT, Tsai S-Y, Segovia JA, et al. Integatin Activation by the Lipid Molecule 25-Hydroxycholesterol Induces a Proinflammatory Response. Nat Commun (2019) 10(1):1482. doi: 10.1038/s41467-019-09453-x

214. Abrams ME, Johnson KA, Perelman SS, Zhang L-S, Endapally S, Mar KB, et al. Oxysterol Sensing Through the Receptor Gpr183 Promotes the Lipid-Sensing-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. Immunity (2018) 48(1):120–32.e8. doi: 10.1016/j.immuni.2017.11.020

215. Wang H, Yuan Z, Patel MA, Jablonski SM, Jablonski JH, Hobson R, et al. The Role of High Cholesterol in Age-Related Covid19 Lethality. bioRxiv (2021). doi: 10.1101/2020.05.09.086249

216. Reiner Z, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Statins and the Covid-19 Main Protease: Evidence on Direct Interaction. Arch Med Sci (2020) 16(3):490–6. doi: 10.5101/amrs.2020.04655

217. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res (2017) 120(1):229–43. doi: 10.1161/CIRCRESAHA.116.308537

218. Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, et al. Impact of Statins on Cardiovascular Outcomes Following Coronavirus Artery Calcium Scoring. J Am Coll Cardio (2018) 72(25):3233–42. doi: 10.1016/j.jacc.2018.09.051

219. Mullien PJ, Garcia G, Pukayastha A, Matulionis N, Schmid EW, Momcilovic M, et al. Sars-CoV-2 Infection Rewires Host Cell Metabolism and Is Potentially Susceptible to Mtorc1 Inhibition. Nat Commun (2021) 12 (1):1876. doi: 10.1038/s41467-021-22166-4

220. Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, et al. Cutting Edge: Severe Sars-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. J Immunol (2021) 206(2):329–34. doi: 10.4049/jimmunol.2001025

221. Sohrabi R, Reinecke H, Godfrey R. Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in Covid-19. Trends Endocrinol Metab (2021) 32(3):32–42. doi: 10.1016/j.tem.2021.01.001

222. Nguyen M, Bourjeddin A, Piroth L, Bouhemad B, Jalil A, Pallet G, et al. High Plasma Concentration of Non-Esterified Polysaturated Fatty Acids Is a Specific Feature of Severe Covid-19 Pneumonia. Sci Rep (2021) 11(1):10824. doi: 10.1038/s41598-021-90362-9

223. Tanaka S, De Tevmo WCS, Assadi M, Zappella N, Jean-Baptiste S, Robert T, et al. Lipoprotein Concentrations Over Time in the Intensive Care Unit Covid-19 Patients: Results From the Apocovid Study. PLoS One (2020) 15(9): e0239573. doi: 10.1177/journal.pone.0239573

224. Marcello A, Civa A, Milan Bonotto R, Nascimento Alves L, Rajasekharan S, Giacobone C, et al. The Cholesterol Metabolite 27'-Hydroxycholesterol Inhibits Sars-CoV-2 and Is Markedly Decreased in Covid-19 Patients. Redox Biol (2020) 36:101682. doi: 10.1016/j.redox.2020.101682

225. Hu X, Chen D, Wu L, He G, Ye W. Declined Serum High Density Lipoprotein Cholesterol Is Associated With the Severity of Covid-19 Infection. Clin Chim Acta; Int J Clin Chem (2020) 510:105. doi: 10.1016/j.cca.2020.07.015

226. Hu X, Chen D, Wu L, He G, Ye W. Low Serum Cholesterol Level Among Patients With Covid-19 Infection in Wenzhou, China. Soc Sci Electronic Publishing (2020). doi: 10.2139/sser.0239573

227. Wang G, Zhang Q, Zhao X, Dong H, Wu C, Wu F, et al. Low High-Density Lipoprotein Level Is Correlated With the Severity of Covid-19 Patients: An Observational Study. Lipids Health Dis (2020) 19(1):204. doi: 10.1186/s12944-020-01382-9

228. Rassaie Q, Dudoignon E, Moreno N, Coutrot M, Dépre F. Low Total Cholesterol Blood Level Is Correlated With Pulmonary Severity in Covid-19 Critical Ill Patients. Anaesth Crit Care Pain Med (2020) 39(6):733–5. doi: 10.1016/j.accpm.2020.07.015

229. Correa Y, Waldeck S, Thépaut M, Micculla S, Moulin M, Fieschi F, et al. Sars-CoV-2 Spike Protein Removes Lipids From Model Membranes and Interfaces With the Capacity of High Density Lipoprotein to Exchange Lipids. J Colloid Interface Sci (2021) 602:732–9. doi: 10.1016/j.jcis.2021.06.056
244. Ding X, Zhang J, Liu L, Yuan X, Zang X, Lu F, et al. High-Density Lipoprotein Cholesterol as a Factor Affecting Virus Clearance in Covid-19 Patients. Respir Med (2020) 175:106218. doi: 10.1016/j.rmed.2020.106218

245. Zhang B, Dong C, Li S, Song X, Wei W, Liu L. Triglyceride to High-Density Lipoprotein Cholesterol Ratio Is an Important Determinant of Cardiovascular Risk and Poor Prognosis in Coronavirus Disease-19: A Retrospective Case Series Study. Diabetes Metab Syndr Obes (2020) 13:3925–36. doi: 10.2147/DMSO.S268992

246. Scalsky RJ, Chen Y-J, Desai K, O’Connell JR, Perry JA, Hong CC. Baseline Cardiometabolic Profiles and Sars-CoV-2 Risk in the Uk Biobank. medRxiv (2020). doi: 10.1101/2020.07.25.20161091

247. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia Is Associated With the Severity of Covid-19. J Clin Lipidol (2020) 14(3):297–304. doi: 10.1016/j.jclip.2020.04.008

248. Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Letter to the Editor: Low-Density Lipoprotein Is a Potential Predictor of Poor Prognosis in Patients With Coronavirus Disease 2019. Metabolism (2020) 107:154243. doi: 10.1016/j.metabol.2020.154243

249. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent Regulation of Sterol Regulatory Element-Binding Proteins 1 and 2 in Hamster Liver. Proc Natl Acad Sci USA (1995) 92(4):935–8. doi: 10.1073/pnas.92.4.935

250. Brown MS, Goldstein JL. The Srebp Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell (1997) 89(3):331–40. doi: 10.1016/S0092-8674(00)80213-5

251. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, et al. Srebp-1, a Basic-Helix-Loop-Helix-Leucine Zipper Protein That Controls Transcription of the Low Density Lipoprotein Receptor Gene. Cell (1993) 75(1):187–97. doi: 10.1016/S0092-8674(05)80095-9

252. Horton JD, Goldstein JL, Brown MS. Srebps: Activators of the Complete Program of Cholesterol and Fatty Acid Synthesis in the Liver. J Clin Invest (2002) 109(9):1125–31. doi: 10.1172/JCI021593

253. Nardacci R, Colavita F, Castillett C, Lapa D, Matusali G, Meschi S, et al. Evidences for Lipid Involvement in Sars-CoV-2 Cytopathogenesis. Cell Death Dis (2021) 12(3):263. doi: 10.1038/s41419-021-03527-9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Dai, Wang, Liao, Tan, Sun, Song, Liu, Qiu and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.